BNTX vs. DXCM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BNTX and DXCM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
BNTX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, DXCM is a standard domestic listing.
| Symbol | BNTX | DXCM |
|---|---|---|
| Company Name | BioNTech SE | DexCom, Inc. |
| Country | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 24.64 billion USD | 22.94 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | October 10, 2019 | April 14, 2005 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of BNTX and DXCM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BNTX | DXCM |
|---|---|---|
| 5-Day Price Return | -1.88% | 5.87% |
| 13-Week Price Return | -9.19% | -28.28% |
| 26-Week Price Return | 9.09% | -30.97% |
| 52-Week Price Return | -7.53% | -19.95% |
| Month-to-Date Return | -0.79% | -0.27% |
| Year-to-Date Return | -9.53% | -25.34% |
| 10-Day Avg. Volume | 0.98M | 9.61M |
| 3-Month Avg. Volume | 0.84M | 5.46M |
| 3-Month Volatility | 40.02% | 50.52% |
| Beta | 1.42 | 1.48 |
Profitability
Return on Equity (TTM)
BNTX
-3.04%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
BNTX has a negative Return on Equity of -3.04%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
DXCM
29.82%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
In the upper quartile for the Health Care Equipment & Supplies industry, DXCM’s Return on Equity of 29.82% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
BNTX
8.52%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
BNTX’s Net Profit Margin of 8.52% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
DXCM
15.96%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
A Net Profit Margin of 15.96% places DXCM in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BNTX
3.75%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
BNTX’s Operating Profit Margin of 3.75% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
DXCM
17.22%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
DXCM’s Operating Profit Margin of 17.22% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BNTX | DXCM |
|---|---|---|
| Return on Equity (TTM) | -3.04% | 29.82% |
| Return on Assets (TTM) | -2.64% | 10.27% |
| Net Profit Margin (TTM) | 8.52% | 15.96% |
| Operating Profit Margin (TTM) | 3.75% | 17.22% |
| Gross Profit Margin (TTM) | 86.80% | 60.20% |
Financial Strength
Current Ratio (MRQ)
BNTX
7.12
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
BNTX’s Current Ratio of 7.12 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
DXCM
1.56
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
DXCM’s Current Ratio of 1.56 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BNTX
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
DXCM
0.92
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
DXCM’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.92. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
BNTX
-1.43
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
DXCM
978.00
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
With an Interest Coverage Ratio of 978.00, DXCM demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | BNTX | DXCM |
|---|---|---|
| Current Ratio (MRQ) | 7.12 | 1.56 |
| Quick Ratio (MRQ) | 7.02 | 1.36 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 0.92 |
| Interest Coverage Ratio (TTM) | -1.43 | 978.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BNTX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
DXCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BNTX
17.60%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
DXCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BNTX | DXCM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 17.60% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BNTX
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for BNTX is currently unavailable.
DXCM
31.42
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
DXCM’s P/E Ratio of 31.42 is within the middle range for the Health Care Equipment & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BNTX
7.89
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
BNTX’s P/S Ratio of 7.89 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
DXCM
5.01
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
DXCM’s P/S Ratio of 5.01 aligns with the market consensus for the Health Care Equipment & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BNTX
1.11
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
BNTX’s P/B Ratio of 1.11 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
DXCM
9.68
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
DXCM’s P/B Ratio of 9.68 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | BNTX | DXCM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 31.42 |
| Price-to-Sales Ratio (TTM) | 7.89 | 5.01 |
| Price-to-Book Ratio (MRQ) | 1.11 | 9.68 |
| Price-to-Free Cash Flow Ratio (TTM) | 24.88 | 21.32 |